ATE546154T1 - Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung - Google Patents

Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung

Info

Publication number: ATE546154T1
Authority: AT; Austria
Prior art keywords: sequence; fragment; angiogenesis; providing; exhibits
Prior art date: 2003-08-01

Application number

AT04786012T

Other languages

English (en)

Inventor

Jean Plouet

Maryvonne Laurent-Beubry

Cecile Martinerie-Kryceve

Original Assignee

Centre Nat Rech Scient

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-01

Filing date

2004-07-30

Publication date

2012-03-15

2004-07-30 Application filed by Centre Nat Rech Scient, Inst Nat Sante Rech Med filed Critical Centre Nat Rech Scient

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE546154T1 publication Critical patent/ATE546154T1/de

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000012634 fragment Substances 0.000 abstract 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
230000033115 angiogenesis Effects 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 3
230000003511 endothelial effect Effects 0.000 abstract 2
230000005764 inhibitory process Effects 0.000 abstract 2
230000007170 pathology Effects 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
230000004913 activation Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT04786012T 2003-08-01 2004-07-30 Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung ATE546154T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0309506A FR2858234B1 (fr)	2003-08-01	2003-08-01	Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
PCT/FR2004/002050 WO2005011725A2 (fr)	2003-08-01	2004-07-30	Agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers

Publications (1)

Publication Number	Publication Date
ATE546154T1 true ATE546154T1 (de)	2012-03-15

Family

ID=34043730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04786012T ATE546154T1 (de)	2003-08-01	2004-07-30	Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung

Country Status (8)

Country	Link
US (1)	US7507712B2 (de)
EP (1)	EP1648494B1 (de)
JP (2)	JP4960091B2 (de)
AT (1)	ATE546154T1 (de)
ES (1)	ES2384932T3 (de)
FR (1)	FR2858234B1 (de)
PT (1)	PT1648494E (de)
WO (1)	WO2005011725A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2858234B1 (fr) *	2003-08-01	2007-09-14	Centre Nat Rech Scient	Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
GB0618748D0 (en) *	2006-09-22	2006-11-01	Univ Belfast	Peptide
US9114112B2 (en)	2010-04-02	2015-08-25	Rosalind Franklin University Of Medicine And Science	CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
ES2561437T3 (es) *	2010-04-02	2016-02-26	Rosalind Franklin University Of Medicine And Science	Péptidos de CCN3 y análogos de los mismos para uso terapéutico
JP5757624B2 (ja) *	2011-04-22	2015-07-29	独立行政法人国立高等専門学校機構	抗アレルギー因子のスクリーニング方法
WO2014177178A1 (en)	2013-04-29	2014-11-06	Sisene Sas	Use of fragments of nov/ccn3 protein for treating pathologies
US10028906B2 (en)	2016-03-22	2018-07-24	Rosalind Franklin University Of Medicine And Science	Method and kit for treating a solid tumor and associated desmoplasia
EP3711772A1 (de) *	2019-03-20	2020-09-23	Oslo Universitetssykehus HF	Rekombinante proteine und fusionsproteine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996039486A1 (en) *	1995-06-05	1996-12-12	Human Genome Sciences, Inc.	Human ccn-like growth factor
EP1382347A1 (de) *	2002-07-17	2004-01-21	UNIVERSITE PARIS 7 - Denis DIDEROT	Verwendung von Mitgliedern der CCN-Protein-Familie zur Behandlung von Erkrankungen im Zusammenhang mit verändertem Kalzium und/oder Natrium-Flux
FR2858234B1 (fr) *	2003-08-01	2007-09-14	Centre Nat Rech Scient	Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers

2003
- 2003-08-01 FR FR0309506A patent/FR2858234B1/fr not_active Expired - Lifetime
2004
- 2004-07-30 US US10/566,679 patent/US7507712B2/en not_active Expired - Lifetime
- 2004-07-30 JP JP2006522370A patent/JP4960091B2/ja not_active Expired - Lifetime
- 2004-07-30 EP EP04786012A patent/EP1648494B1/de not_active Expired - Lifetime
- 2004-07-30 WO PCT/FR2004/002050 patent/WO2005011725A2/fr not_active Ceased
- 2004-07-30 PT PT04786012T patent/PT1648494E/pt unknown
- 2004-07-30 ES ES04786012T patent/ES2384932T3/es not_active Expired - Lifetime
- 2004-07-30 AT AT04786012T patent/ATE546154T1/de active
2011
- 2011-05-20 JP JP2011113202A patent/JP2011231113A/ja active Pending

Also Published As

Publication number	Publication date
PT1648494E (pt)	2012-05-28
ES2384932T3 (es)	2012-07-16
EP1648494A2 (de)	2006-04-26
US7507712B2 (en)	2009-03-24
EP1648494B1 (de)	2012-02-22
WO2005011725A3 (fr)	2005-09-09
FR2858234A1 (fr)	2005-02-04
JP2011231113A (ja)	2011-11-17
US20070059314A1 (en)	2007-03-15
WO2005011725A2 (fr)	2005-02-10
JP4960091B2 (ja)	2012-06-27
FR2858234B1 (fr)	2007-09-14
JP2007501203A (ja)	2007-01-25

Publication	Publication Date	Title
GB0222495D0 (en)	2002-11-06	Compounds
DE60028970D1 (de)	2006-08-03	An her2 bindende peptidverbindungen
UA83194C2 (ru)	2008-06-25	Производные пиримидина и их применение как модуляторов св2
ATE408601T1 (de)	2008-10-15	Fredericamycin-derivate
DE602004032107D1 (de)	2011-05-19	Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
ATE453653T1 (de)	2010-01-15	Platinkomplexe zur behandlung von tumoren
CY1110177T1 (el)	2015-01-14	Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1111225T1 (el)	2015-06-11	Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
EA200601553A1 (ru)	2006-12-29	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EA201070636A1 (ru)	2010-10-29	Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
ATE448232T1 (de)	2009-11-15	Substituierte heterozyklen
TW200611695A (en)	2006-04-16	Pyrrolopyridine derivatives
ATE546154T1 (de)	2012-03-15	Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
DK1234025T3 (da)	2008-11-17	Humane enzymer fra metalloproteasefamilien
ATE290857T1 (de)	2005-04-15	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50205466D1 (de)	2006-02-02	Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE427956T1 (de)	2009-04-15	Ckrox-peptide und ihre analoge zur behandlung von hautalterung
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
NO20026286D0 (no)	2002-12-30	Nye peptider
DE60312684D1 (de)	2007-05-03	Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE482976T1 (de)	2010-10-15	Defensinproteine
DE60213365D1 (de)	2006-09-07	Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE410235T1 (de)	2008-10-15	Behandlung von ballastwasser
UA85187C2 (en)	2009-01-12	2-aminobenzoyl derivatives